Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OASIS-3 long-term extension of mirikizumab for moderate to severe plaque psoriasis
MOH_2019-11-13_007488Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of mirikizumab in plaque psoriasis, sponsored by Eli Lilly and Company. Primary endpoint: Maintenance of efficacy over time. Started Aug 2019; status: completed.
02
Drugs
mirikizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on MOH_2019-11-13_007488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-11-13_007488.